The latest update is out from Pharmaust Limited ( (AU:NUZ) ).
Neurizon Therapeutics Limited announced promising results from an independent study conducted with The University of Queensland, examining the effects of their compound NUZ-001 on mouse motor neuron cells. The study found that NUZ-001 had a significant survival effect on TDP-43-mediated cell death, independent of autophagy activation, suggesting other pharmacological processes may be involved. These findings, presented at the AD/PD 2025 conference, are expected to enhance Neurizon’s visibility and support ongoing clinical development and partnership discussions.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a clinical-stage biotech company focused on developing innovative treatments for neurodegenerative diseases. The company collaborates with research institutions to explore pharmacological activities that could advance therapeutic approaches for conditions such as Amyotrophic Lateral Sclerosis (ALS).
YTD Price Performance: -27.78%
Average Trading Volume: 5,836
Technical Sentiment Signal: Strong Buy
Current Market Cap: €35.38M
Learn more about NUZ stock on TipRanks’ Stock Analysis page.